Cited by 466Chronic Kidney Disease and DiabetesHormonal Regulation and HypertensionRenin-Angiotensin System Studies

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy

Sato, Atsuhisa, Hayashi, Koichi, Naruse, Mitsuhide, Saruta, Takao·2003·Hypertension

Open this paper in CoChat — free account

Abstract

It has been reported that continuous ACE inhibitor therapy does not necessarily produce a maintained decrease in plasma aldosterone levels, which may remain high or increase eventually during long-term use (aldosterone escape). We have examined the role of aldosterone escape in 45 patients with type 2 diabetes and early nephropathy treated with an ACE inhibitor for 40 weeks. With treatment, there was a 40% reduction in average urinary albumin excretion, although urinary albumin excretion in patients with aldosterone escape (18 patients) was significantly higher than that in patients without escape (27 patients). In the 18 patients with escape, spironolactone (25 mg/d) was added to ACE inhibitor treatment in 13. After a 24-week study period, urinary albumin excretion and left ventricular mass index were significantly reduced without blood pressure change. In conclusion, the present study demonstrates that aldosterone escape is observed in 40% of patients with type 2 diabetes with early nephropathy despite the use of ACE inhibitors. Our study suggests the possibility that aldosterone blockade may represent optimal therapy for patients with early diabetic nephropathy who show aldosterone escape during ACE inhibitor treatment and who no longer show maximal antiproteinuric effects of ACE inhibition. Additional, larger, prospectively randomized, double-blind studies will be needed before adaptation of this strategy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.hyp.0000044937.95080.e9

Cites

0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339

Show all 0 references

Research works printed but not linked: 27

10.1172/JCI104436 · DOI
10.3109/10641969709083193 · DOI
Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med. 1992; 120: 893–901.
10.1291/hypres.23.25 · DOI
10.1177/147323000102900103 · DOI
10.1291/hypres.24.99 · DOI
10.1291/hypres.22.17 · DOI
10.1097/00004872-200105000-00001 · DOI
10.1210/endo.141.10.7711 · DOI
10.1161/hyp.35.5.1078 · DOI
10.1161/circ.100.10.1134 · DOI
10.1053/ajkd.2001.22069 · DOI
Guidelines Subcommittee. World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999; 1999: 17:151–183.
10.1001/archinte.1987.00370050135022 · DOI
10.1056/NEJM198312223092503 · DOI
10.2337/diacare.25.2007.S85 · DOI
10.1161/01.CIR.58.6.1072 · DOI
10.1161/01.CIR.55.4.613 · DOI
10.1016/0002-9149(82)90390-3 · DOI
10.1016/S1071-9164(96)80009-1 · DOI
10.1002/j.1552-4604.1993.tb03901.x · DOI
10.1016/S0735-1097(01)01714-4 · DOI
10.1016/S0735-1097(01)01237-2 · DOI
10.1056/NEJM200109203451215 · DOI
Arutyunov G, Chernyavskaya T, Korsunskaya M, Rylova A. Study of the efficacy and safety of RAAS long-term complete blockade in type II diabetic patients with MAU and essential hypertension. Eur Heart J. 2000; 21: 91.Abstract.
10.1046/j.1523-1755.2000.00055.x · DOI
10.1210/endo.137.10.8828470 · DOI

Sorted by citations

Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
Ogihara, T., Kikuchi, K. M., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., Iwao, H., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,384
Self-citation
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)
(2014) · Hypertension Research · doi:10.1038/hr.2014.20 · Cited by 1,049
Self-citation
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Inflammatory cells in ischemic acute renal failure.
Friedewald, J., & Rabb, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.761_3.x · Cited by 457
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M. H., Lewin, A. J., Krause, S. L., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 463
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0575 · Cited by 426
Long-term Renal Outcomes in Patients With Primary Aldosteronism
Sechi, L. A., Novello, M., Lapenna, R., Baroselli, S., Nadalini, E., Colussi, G., & Catena, C. (2006) · JAMA · doi:10.1001/jama.295.22.2638 · Cited by 395
“003) and in patients with adrenal adenoma (from a mean [SD] of 103 [15] to 90 [18] mL/min per 1.”
Background
Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan
Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D., & Navis, G. J. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007060693 · Cited by 374
New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology
Wolf, G. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01429.x · Cited by 360
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease
Bianchi, S., Bigazzi, R., & Campese, V. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001854 · Cited by 342
“12 20 In a pilot short-term uncontrolled study, we observed that spironolactone effectively reduced proteinuria in non-diabetic CKD patients already treated with ACEIs and/or ARBs.”
Background
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications
Wolf, G., & Ritz, E. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00145.x · Cited by 287
“Additional administration of spironolactone reduced proteinuria in these patient”
Background
The renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 473
Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy
Rossing, K., Schjoedt, K. J., Smidt, U., Boomsma, F., & Parving, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 298
“However, albuminuria was reduced in 17 of 20 patients who completed the study, and therefore our study suggests that the antiproteinuric effect is not restricted to patients with aldosterone escape, which has been reported to occur in 40% of patients receiving chronic ACE inhibitor or ARB treatment(11,12).”
BackgroundResultInfluential
Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers
Twigg, S. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1991 · Cited by 291
“Drugs that either inhibit the formation of AGE or break AGE-induced cross-links have been shown to be renoprotective in experimental models of diabetic nephropathy (Forbes et al 2002).”
Aldosterone in the development and progression of renal injury
Hollenberg, N. K. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00701.x · Cited by 275
“Preliminary data indicate that spironolactone decreases proteinuria in patients with both chronic renal disease [66] and those with type 2 diabetes and early nephropathy [67].”
Background
Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
Bärfacker, L., Kühl, A., Hillisch, A., Grosser, R., Figueroa‐Pérez, S., Heckroth, H., Nitsche, A., Ergüden, J., Gielen‐Haertwig, H., Schlemmer, K., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200081 · Cited by 276
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Naaman, S., & Bakris, G. L. (2023) · Diabetes Care · doi:10.2337/dci23-0030 · Cited by 308
Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261
Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes*
Mogensen, C. E. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01157.x · Cited by 227
Enhanced Aldosterone Signaling in the Early Nephropathy of Rats with Metabolic Syndrome
Nagase, M., Yoshida, S., Shibata, S., Nagase, T., Gotoda, T., Ando, K., & Fujita, T. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080944 · Cited by 247
Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management
Buren, P. N. V., & Toto, R. (2011) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.10.003 · Cited by 266
“” Aldosterone escape occurs in up to 40% of patients on ACEi or ARBs and may contribute to local renal damage, albuminuria increases, and possibly systemic hypertenson (84,85).”
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Barrera‐Chimal, J., Girerd, S., & Jaisser, F. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.030 · Cited by 267
Beneficial impact of spironolactone in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P. R., Tarnow, L., & Parving, H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00756.x · Cited by 237
“Results from recent open-labeled studies suggest a beneficial effect of aldosterone antagonism in various nephropathies, including type 2 diabetic patients with macro- and microalbuminuria [6, 16, 17].”
BackgroundMethodResultInfluential
Aldosterone escape during blockade of the renin?angiotensin?aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate
Schjoedt, K. J., Andersen, S., Rossing, P. R., Tarnow, L., & Parving, H. (2004) · Diabetologia · doi:10.1007/s00125-004-1542-0 · Cited by 246
“In long-term clinical trials with blockade of the renin–angiotensin–aldosterone system (RAAS) by angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II (AngII) receptor antagonists (ARBs) [3, 4, 5] or the combination of both [5], plasma aldosterone levels have been shown to increase in some patients after…”
Background
The intrarenal renin–angiotensin system and diabetic nephropathy
Carey, R. M., & Siragy, H. M. (2003) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(03)00111-5 · Cited by 231
Management of Glomerular Proteinuria: A Commentary
Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000100145.27188.33 · Cited by 217
“Eplerenone (currently under study) is similar to that of spironolactone, but with fewer side effects (128), and is antiproteinuric (129,130).”
Background
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Tarnow, L., Rossing, P. R., & Parving, H.-H. (2006) · Kidney International · doi:10.1038/sj.ki.5001580 · Cited by 212
Endothelial dysfunction as a potential contributor in diabetic nephropathy
Nakagawa, T., Tanabe, K., Croker, B. P., Johnson, R. J., Grant, M. B., Kosugi, T., & Li, Q. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.152 · Cited by 194
“This phenomenon occurs in approximately 40% of patients with diabetes who are treated with drugs that block the RAS”
Ca2+Channel Subtypes and Pharmacology in the Kidney
Hayashi, K., Wakino, S., Sugano, N., Ozawa, Y., Homma, K., & Saruta, T. (2007) · Circulation Research · doi:10.1161/01.res.0000256155.31133.49 · Cited by 207
Self-citation
Double-Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist Spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor Blocker
Chrysostomou, A., Pedagogos, E., MacGregor, L., & Becker, G. J. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01040905 · Cited by 209
Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells.
Miyata, K., Rahman, M., Shokoji, T., Nagai, Y., Zhang, G.-X., Sun, G.-P., Kimura, S., Yukimura, T., Kiyomoto, H., Kohno, M., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005040390 · Cited by 187
“In patients with chronic renal failure (13) and early diabetic nephropathy (14), addition of a nonselective MR antagonist, spironolactone, to ACE inhibitors did not exert hemodynamic effects, but markedly reduced urinary excretion”
Background
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Nowack, C., Kolkhof, P., Ferreira, A. C., Schloemer, P., Filippatos, G., et al. (2019) · American Journal of Nephrology · doi:10.1159/000503713 · Cited by 184
Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study
Bianchi, S., Bigazzi, R., & Campese, V. M. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.03.007 · Cited by 140
Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function
van den Meiracker, A. H., Baggen, R. G. A., Pauli, S., Lindemans, A. D., Vulto, A. G., Poldermans, D., & Boomsma, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249708.44016.5c · Cited by 188
Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage
Fiebeler, A., Nussberger, J., Shagdarsuren, E., Rong, S., Hilfenhaus, G., Al‐Saadi, N., Dechend, R., Wellner, M., Meiners, S., Maser‐Gluth, C., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.521625 · Cited by 186
Aldosterone Synthase Inhibition With LCI699
Amar, L., Azizi, M., Ménard, J., Peyrard, S., Watson, C. E., & Plouin, P. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.157271 · Cited by 208
Transforming growth factor-β1 and diabetic nephropathy
Chang, A. S., Hathaway, C. K., Smithies, O., & Kakoki, M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00502.2015 · Cited by 193
“Indeed, chronic administration of spironolactone, a mineralocorticoid receptor antagonist, decreased albuminuria in patients with diabetes (89).”
Background
Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Han, S., Kim, C., Kim, H.-S., Jee, Y., Song, H., Lee, M.-H., Han, K., Kim, H., Kang, Y. S., Han, J., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005111196 · Cited by 172
Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus
Guo, C., Martinez-Vasquez, D., Méndez, G. P., Toniolo, M. F., Yao, T. M., Oestreicher, E. M., Kikuchi, T., Lapointe, N., Pojoga, L. H., Williams, G. H., et al. (2006) · Endocrinology · doi:10.1210/en.2006-0944 · Cited by 176
Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: An overview
Odermatt, A., & Kratschmar, D. V. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.020 · Cited by 163
Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy
Nagai, K., Matsubara, T., Mima, A., Sumi, E., Kanamori, H., Iehara, N., Fukatsu, A., Yanagita, M., Nakano, T., Ishimoto, Y., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00433.x · Cited by 148
“Warfarin treatment of the rats resulted in a significant decrease in glomerular size as previously shown [11].”
BackgroundResult
Aldosterone and end-organ damage
Brown, N. J. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000165889.60254.98 · Cited by 321
The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study
Rachmani, R., Slavachevsky, I., Amit, M., Levi, Z., Kedar, Y., Berla, M., & Ravid, M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01194.x · Cited by 140
Retracted
The Role of Aldosterone in Obesity-Related Hypertension
Kawarazaki, W., & Fujita, T. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw003 · Cited by 170
The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure
Cat, A. N. D., Griol‐Charhbili, V., Loufrani, L., Labat, C., Benjamin, L. E., Farman, N., Lacolley, P. J., Henrion, D., & Jaisser, F. (2010) · The FASEB Journal · doi:10.1096/fj.09-147926 · Cited by 167
New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone
Bobadilla, N. A., & Gamba, G. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00072.2007 · Cited by 132
“In humans, pilot studies showed that the addition of spironolactone to angiotensin-converting enzyme inhibitors had no hemodynamic effects but markedly reduced proteinuria in patients with renal failure (8) and in patients with type 2 diabetes (53).”
Background
Aldosterone Stimulates Collagen Gene Expression and Synthesis Via Activation of ERK1/2 in Rat Renal Fibroblasts
Nagai, Y., Miyata, K., Sun, G.-P., Rahman, M., Kimura, S., Miyatake, A., Kiyomoto, H., Kohno, M., Abe, Y., Yoshizumi, M., et al. (2005) · HYPERTENSION · doi:10.1161/01.hyp.0000174593.88899.68 · Cited by 142
Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
Bertocchio, J., Warnock, D. G., & Jaisser, F. (2011) · Kidney International · doi:10.1038/ki.2011.48 · Cited by 143
Involvement of Aldosterone and Mineralocorticoid Receptors in Rat Mesangial Cell Proliferation and Deformability
Nishiyama, A., Yao, L., Fan, Y.-Y., Kyaw, M. H., Kataoka, N., Hashimoto, K., Nagai, Y., Nakamura, E., Yoshizumi, M., Shokoji, T., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000154681.38944.9a · Cited by 143
Aldosterone in Chronic Kidney and Cardiac Disease
Hostetter, T. H., & Ibrahim, H. N. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000086472.65806.73 · Cited by 137
“(50) identified 13 patients with type II diabetes mellitus who were treated with an ACE inhibitor but whose aldosterone levels increased after initial suppression (i.”
Background
Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease
Sato, A., Hayashi, K., & Saruta, T. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.06.029 · Cited by 132
“In this study, we have confirmed the effectiveness of aldosterone blockade in selective patients with diabetic nephropathy, as shown in our previous study.(12) We previously demonstrated that high glucose levels potentiate the effects of aldosterone on leucine incorporation by neonatal rat cardiomyocytes in culture,(2…”
BackgroundMethodResultInfluentialSelf-citation
Increased Expression of Mineralocorticoid Effector Mechanisms in Kidney Biopsies of Patients With Heavy Proteinuria
Quinkler, M. O., Zehnder, D., Eardley, K. S., Lepenies, J., Howie, A. J., Hughes, S. V., Cockwell, P., Hewison, M., & Stewart, P. M. (2005) · Circulation · doi:10.1161/circulationaha.105.539122 · Cited by 137
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy
Sato, A. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)00913-0 · Cited by 129
“When we administered trandolapril for 40 weeks to 45 patients with early diabetic nephropathy, aldosterone breakthrough was observed in 18 (40%).(24) This is evidence for the appearance of this phenomenon even in patients with diabetic nephropathy.”
BackgroundMethodSelf-citation
Local Renal Aldosterone System and Its Regulation by Salt, Diabetes, and Angiotensin II Type 1 Receptor
Xue, C., & Siragy, H. M. (2005) · Hypertension · doi:10.1161/01.hyp.0000175814.18550.c0 · Cited by 122
Recent advances in diabetic nephropathy
Marshall, S. M. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.021287 · Cited by 98
Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury.
Sun, G.-P., Kohno, M., Guo, P., Nagai, Y., Miyata, K., Fan, Y., Kimura, S., Kiyomoto, H., Ohmori, K., Li, D.-T., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121375 · Cited by 119
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial
Ando, K., Ohtsu, H., Uchida, S., Kaname, S., Arakawa, Y., & Fujita, T. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70194-9 · Cited by 130
A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
Katayama, S., Yamada, D., Nakayama, M., Yamada, T., Myoishi, M., Kato, M. C., Nowack, C., Kolkhof, P., & Yamasaki, Y. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.021 · Cited by 133
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Wang, N., & Zhang, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063086 · Cited by 116
“Long periods of use of trandolapril showed an obvious increase in aldosterone in 40% of patients at 40 weeks with mounting albumin-uria [147], which indicated that the combined use of ACEI/ARBs and MRAs might present optimal treatment for DKD.”
Background
Aldosterone in chronic kidney disease and renal outcomes
Verma, A., Vaidya, A., Subudhi, S., & Waikar, S. S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac352 · Cited by 130
Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension
Colussi, G., Catena, C., & Sechi, L. A. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283599b6a · Cited by 112
Identification of Benzoxazin-3-one Derivatives as Novel, Potent, and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
Hasui, T., Matsunaga, N., Ora, T., Ohyabu, N., Nishigaki, N., Imura, Y., Igata, Y., Matsui, H., Motoyaji, T., Tanaka, T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2011645 · Cited by 116
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity
Pérez‐Rojas, J. M., Blanco, J. A., Cruz, C., Trujillo, J., Vaidya, V. S., Uribe, N., Bonventre, J. V., Gamba, G., & Bobadilla, N. A. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00147.2006 · Cited by 112
“Pilot studies in humans showed that addition of spironolactone to ACE inhibitors had no hemodynamic effects but markedly reduced proteinuria in patients with renal failure (4) and in patients with type 2 diabetes (39).”
Relationships of plasma renin levels with renal function in patients with primary aldosteronism.
Catena, C., Colussi, G., Nadalini, E., Chiuch, A., Baroselli, S., Lapenna, R., & Sechi, L. (2007) · American Society of Nephrology. Clinical Journal · doi:10.2215/cjn.00050107 · Cited by 108
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives
Epstein, M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg339 · Cited by 60
“[60] investigated the role of aldosterone rebound in 45 patients with type 2 diabetes and early nephropathy treated with an ACE inhibitor for 40 weeks.”
Background
Effect of Aldosterone and Mineralocorticoid Receptor Blockade on Vascular Inflammation
Joffe, H. V., & Adler, G. K. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2346-0 · Cited by 114
The Ubiquitous Mineralocorticoid Receptor: Clinical Implications
Hawkins, U. A., Gómez-Sánchez, E. P., Gomez-Sanchez, C. M., & Gómez-Sánchez, C. E. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0297-0 · Cited by 117
“Current recommendations for the treatment of hypertensive diabetics include the use of ACEi or ARB to block the renin-angiotensin system; however, in diabetics with proteinuria incompletely corrected with an ACEi, the addition of spironolactone has clear additive effects on decreasing protein excretion, with an additi…”
Aldosterone synthase inhibition in humans
Azizi, M., Amar, L., & Ménard, J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs388 · Cited by 104
Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats.
Han, K., Kang, Y. S., Han, S., Jee, Y., Lee, M. H., Han, J., Kim, H., Kim, Y. S., & Cha, D. (2006) · Kidney International · doi:10.1038/sj.ki.5000438 · Cited by 98
“13 Aldosterone receptor blockade also provides beneficial effects in patients with diabetic nephropathy”
Background
Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker
Furumatsu, Y., Nagasawa, Y., Tomida, K., Mikami, S., Kaneko, T., Okada, N., Tsubakihara, Y., Imai, E., & Shoji, T. (2008) · Hypertension Research · doi:10.1291/hypres.31.59 · Cited by 97
“In their subsequent report, in patients with aldosterone breakthrough, the addition of spironolactone (25 mg/day) resulted in a 30% decrease in urinary albumin excretion (24).”
Background
Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005
Rossing, P. R. (2005) · Diabetologia · doi:10.1007/s00125-005-0077-3 · Cited by 94
“Blocking the effect of aldosterone with spironolactone (25 mg/day) in 13 type 2 diabetic patients with aldosterone escape during treatment with an ACE inhibitor induced a significant reduction in albuminuria [104].”
Background
Diabetic Kidney Disease: From Epidemiology to Clinical Perspectives
Park, C. W. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.4.252 · Cited by 100
“Clinical trials confirming positive effects of aldosterone blockade are also needed [50].”
Background
Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury
Ma, J., Weisberg, A. D., Griffin, J. P., Vaughan, D. E., Fogo, A. B., & Brown, N. J. (2006) · Kidney International · doi:10.1038/sj.ki.5000201 · Cited by 96
Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats
Taira, M., Toba, H., Murakami, M., Iga, I., Serizawa, R., Murata, S., Kobara, M., & Nakata, T. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.019 · Cited by 93
Plasma aldosterone concentration in the patient with diabetes mellitus Rapid Communication
Hollenberg, N. K., Stevanovic, R. D., Agarwal, A., Lansang, M. C., Price, D. A., Laffel, L. M., Williams, G. H., & Fisher, N. D. L. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00524.x · Cited by 81
“Evidence that an increased aldosterone level contributes to tissue injury in diabetes, and that this is reversed by the addition of an aldosterone antagonist to ACE inhibition therapy is immediately relevant [13].”
Background
Aldosterone-Induced Organ Damage: Plasma Aldosterone Level and Inappropriate Salt Status
Sato, A., & Saruta, T. (2004) · Hypertension Research · doi:10.1291/hypres.27.303 · Cited by 87
Self-citation
Epithelial Sodium Channel Inhibition in Cardiovascular DiseaseA Potential Role for Amiloride
TEIWES, J., & Toto, R. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2006.05.022 · Cited by 94
Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
Ravindran, S., & Munusamy, S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30621 · Cited by 98
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy
Mavrakanas, T. A., Gariani, K., & Martin, P. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.11.007 · Cited by 85
“a rebound in aldosterone plasma levels after a transient decrease, has been detected in 40% of patients with early diabetic nephropathy treated by an ACEI [19].”
Background
Aldosterone breakthrough during therapy with angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy
Horita, Y., Taura, K., Taguchi, T., Furusu, A., & Kohno, S. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00665.x · Cited by 75
Aldosterone and glomerular podocyte injury
Nagase, M., & Fujita, T. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0034-9 · Cited by 79
“Conversely, aldosterone blockers effectively ameliorate proteinuria in patients or animal models of hypertension, diabetes, and renal disease [10, 12, 48–53].”
Background
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease
Liu, L. C. Y., Schutte, E., Gansevoort, R. T., van der Meer, P., & Voors, A. A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1059819 · Cited by 85
“Excessive levels of aldosterone result in conditions as HF, hypertension and CKD [34-38], and inhibition of the activity of the renin-angiotensin-aldosterone system (RAAS) results in improved outcomes.”
BackgroundInfluential
Beneficial Effects of EplerenoneVersusHydrochlorothiazide on Coronary Circulatory Function in Patients with Diabetes Mellitus
Joffe, H. V., Kwong, R. Y. K., Gerhard‐Herman, M. D., Rice, C., Feldman, K., & Adler, G. K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0393 · Cited by 80
Molecular Mechanisms and Therapeutic Strategies of Chronic Renal Injury: Renoprotective Effects of Aldosterone Blockade
Nishiyama, A., & Abe, Y. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fmj05003x3 · Cited by 64
Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021
Banerjee, D., Winocour, P. H., Chowdhury, T. A., De, P., Wahba, M. M., Montero, R., Fogarty, D. G., Frankel, A., Karalliedde, J. J., Mark, P. B., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-021-02587-5 · Cited by 92
“In one study of people who had type 2 diabetes with early nephropathy and normal renal function, adding spironolactone to ACEI treatment was shown to be clinically useful and safe for people who showed aldosterone escape during ACEI treatment and who no longer showed maximal antiproteinuric effects of ACE inhibition […”
Background
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone
Rico-Mesa, J. S., White, A., Ahmadian-Tehrani, A., & Anderson, A. S. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01399-7 · Cited by 85
Heart Failure and Nephropathy
Gilbert, R. E., Connelly, K. A., Kelly, D. J., Pollock, C. A., & Krum, H. (2005) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00540705 · Cited by 66
Aldosterone Antagonism Ameliorates Proteinuria and Nephrosclerosis Independent of Glomerular Dynamics in L-NAME/SHR Model
Zhou, X., Ono, H., Ono, Y., & Frohlich, E. D. (2004) · American Journal of Nephrology · doi:10.1159/000077396 · Cited by 66
Multiple Endocrine Regulation by Bone Morphogenetic Protein System
Otsuka, F. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-310 · Cited by 69
Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism
Fourkiotis, V., Vonend, O., Diederich, S., Fischer, E., Lang, K., Endres, S., Beuschlein, F., Willenberg, H. S., Rump, L. C., Allolio, B., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0631 · Cited by 84
Recovery from ischemic acute kidney injury by spironolactone administration
Sanchez-Pozos, K. A., Barrera‐Chimal, J., Garzon-Muvdi, J., Pérez‐Villalva, R., Rodríguez‐Romo, R., Cruz, C., Gamba, G., & Bobadilla, N. A. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs014 · Cited by 71
Prevention of the development and progression of renal disease.
Hostetter, T. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000070150.60928.06 · Cited by 71
“Nevertheless, encouraging results have appeared from preliminary or very small studies (20).”
Result
The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease
Edwards, N. C., Steeds, R. P., Chue, C. D., Stewart, P. M., Ferro, C. J., & Townend, J. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04102.x · Cited by 75
Aldosterone Antagonism in Chronic Kidney Disease
Ponda, M. P., & Hostetter, T. H. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00120106 · Cited by 75

Authors: Sato, A., Hayashi, K., Naruse, M., & Saruta, T.
Affiliations: Keio University (JP)
From the Department of Internal Medicine, Mito Red Cross Hospital (A.S.), Ibaraki; the Department of Internal Medicine, Keio University (K.H., T.S.), Tokyo; and the Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women’s Medical University (M.N.), Tokyo, Japan.
ORCID: Naruse, Mitsuhide
Venue: Hypertension
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2003-01
Volume: 41
Issue: 1
Pages: 64-68
ISSN: 0194-911X (ISSN-L)
1524-4563
DOI: 10.1161/01.hyp.0000044937.95080.e9
OpenAlex: W2163709605
Cited by: 466
References: 0
Citations by year: 2026: 7 · 2025: 8 · 2024: 5 · 2023: 15 · 2022: 20 · 2021: 9 · 2020: 10 · 2019: 13 · 2018: 11 · 2017: 4 · 2016: 13 · 2015: 16 · 2014: 20 · 2013: 19 · 2012: 28
FWCI: 28.03
Type: journal article
Language: en
Open access: closed
Locations: Hypertension (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords: aldosterone escape, aldosterone blockade, spironolactone, ACE inhibitors, diabetic nephropathy, type 2 diabetes, urinary albumin excretion, proteinuria, left ventricular mass, renin-angiotensin system
MeSH terms: Albuminuria, Aldosterone, Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Drug Therapy, Combination, Female, Heart Ventricles, Humans, Male, Middle Aged, Spironolactone, Ultrasonography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks